The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.

Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.T...

Full description

Bibliographic Details
Main Authors: Fidelis Cho-Ngwa, Jing Liu, Sara Lustigman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-08-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC2927424?pdf=render
_version_ 1818129320169701376
author Fidelis Cho-Ngwa
Jing Liu
Sara Lustigman
author_facet Fidelis Cho-Ngwa
Jing Liu
Sara Lustigman
author_sort Fidelis Cho-Ngwa
collection DOAJ
description Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.Third-stage larvae (L3) and molting L3 (mL3) O. volvulus stage-specific cDNA libraries were screened with a pool of sera from chronically infected patients who had likely developed such immunity. The 87 immunoreactive clones isolated were grouped into 20 distinct proteins of which 12 had already been cloned and/or characterized before and 4 had been proven to be protective in a small O. volvulus animal model. One of these, onchocystatin (Ov-CPI-2), a previously characterized O. volvulus cysteine proteinase inhibitor was, overall, the most abundant clone recognized by the immune sera in both the L3 and mL3 cDNA libraries. To further characterize its association with protective immunity, we measured the IgG subclass and IgE class specific responses to the antigen in putatively immune (PI) and infected (INF) individuals living in a hyperendemic area in Cameroon. It appeared that both groups had similar IgG3 and IgE responses to the antigen, but the INF had significantly higher IgG1 and IgG4 responses than the PI individuals (p<0.05). In the INF group, the IgG3 levels increased significantly with the age of the infected individuals (r = 0.241; p<0.01). The IgG1 responses in the INF were high regardless of age. Notably, culturing L3 in vitro in the presence of anti-Ov-CPI-2 monospecific human antibodies and naïve neutrophils resulted in almost complete inhibition of molting of L3 to L4 and to cytotoxicity to the larvae.These results add to the knowledge of protective immunity in onchocerciasis and support the possible involvement of anti-Ov-CPI-2 IgG1 and/or IgG3 cytophilic antibodies in the development of protective immunity in the PI and the INF. The results further support the consideration of Ov-CPI-2 as a leading target for an anti-L3 vaccine.
first_indexed 2024-12-11T07:47:16Z
format Article
id doaj.art-921ea28a964847f18d3c624f3ea33ffe
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-12-11T07:47:16Z
publishDate 2010-08-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-921ea28a964847f18d3c624f3ea33ffe2022-12-22T01:15:26ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352010-08-0148e80010.1371/journal.pntd.0000800The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.Fidelis Cho-NgwaJing LiuSara LustigmanDespite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.Third-stage larvae (L3) and molting L3 (mL3) O. volvulus stage-specific cDNA libraries were screened with a pool of sera from chronically infected patients who had likely developed such immunity. The 87 immunoreactive clones isolated were grouped into 20 distinct proteins of which 12 had already been cloned and/or characterized before and 4 had been proven to be protective in a small O. volvulus animal model. One of these, onchocystatin (Ov-CPI-2), a previously characterized O. volvulus cysteine proteinase inhibitor was, overall, the most abundant clone recognized by the immune sera in both the L3 and mL3 cDNA libraries. To further characterize its association with protective immunity, we measured the IgG subclass and IgE class specific responses to the antigen in putatively immune (PI) and infected (INF) individuals living in a hyperendemic area in Cameroon. It appeared that both groups had similar IgG3 and IgE responses to the antigen, but the INF had significantly higher IgG1 and IgG4 responses than the PI individuals (p<0.05). In the INF group, the IgG3 levels increased significantly with the age of the infected individuals (r = 0.241; p<0.01). The IgG1 responses in the INF were high regardless of age. Notably, culturing L3 in vitro in the presence of anti-Ov-CPI-2 monospecific human antibodies and naïve neutrophils resulted in almost complete inhibition of molting of L3 to L4 and to cytotoxicity to the larvae.These results add to the knowledge of protective immunity in onchocerciasis and support the possible involvement of anti-Ov-CPI-2 IgG1 and/or IgG3 cytophilic antibodies in the development of protective immunity in the PI and the INF. The results further support the consideration of Ov-CPI-2 as a leading target for an anti-L3 vaccine.http://europepmc.org/articles/PMC2927424?pdf=render
spellingShingle Fidelis Cho-Ngwa
Jing Liu
Sara Lustigman
The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
PLoS Neglected Tropical Diseases
title The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
title_full The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
title_fullStr The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
title_full_unstemmed The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
title_short The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
title_sort onchocerca volvulus cysteine proteinase inhibitor ov cpi 2 is a target of protective antibody response that increases with age
url http://europepmc.org/articles/PMC2927424?pdf=render
work_keys_str_mv AT fidelischongwa theonchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage
AT jingliu theonchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage
AT saralustigman theonchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage
AT fidelischongwa onchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage
AT jingliu onchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage
AT saralustigman onchocercavolvuluscysteineproteinaseinhibitorovcpi2isatargetofprotectiveantibodyresponsethatincreaseswithage